Intrinsic value of Nu Skin Enterprises Cl A - NUS

Previous Close

$68.02

  Intrinsic Value

$871.56

stock screener

  Rating & Target

str. buy

+999%

Previous close

$68.02

 
Intrinsic value

$871.56

 
Up/down potential

+999%

 
Rating

str. buy

We calculate the intrinsic value of NUS stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 3.8

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  28.00
  25.70
  23.63
  21.77
  20.09
  18.58
  17.22
  16.00
  14.90
  13.91
  13.02
  12.22
  11.50
  10.85
  10.26
  9.74
  9.26
  8.84
  8.45
  8.11
  7.80
  7.52
  7.26
  7.04
  6.83
  6.65
  6.49
  6.34
  6.20
  6.08
Revenue, $m
  2,917
  3,667
  4,533
  5,520
  6,629
  7,861
  9,215
  10,690
  12,282
  13,991
  15,813
  17,744
  19,784
  21,930
  24,181
  26,535
  28,992
  31,554
  34,221
  36,995
  39,880
  42,877
  45,992
  49,229
  52,594
  56,092
  59,730
  63,516
  67,456
  71,559
Variable operating expenses, $m
  1,138
  1,426
  1,759
  2,138
  2,564
  3,037
  3,557
  4,123
  4,735
  5,391
  6,072
  6,814
  7,597
  8,421
  9,285
  10,189
  11,133
  12,116
  13,140
  14,206
  15,313
  16,464
  17,660
  18,903
  20,195
  21,539
  22,936
  24,389
  25,902
  27,478
Fixed operating expenses, $m
  1,160
  1,185
  1,212
  1,238
  1,265
  1,293
  1,322
  1,351
  1,381
  1,411
  1,442
  1,474
  1,506
  1,539
  1,573
  1,608
  1,643
  1,679
  1,716
  1,754
  1,793
  1,832
  1,872
  1,913
  1,956
  1,999
  2,043
  2,087
  2,133
  2,180
Total operating expenses, $m
  2,298
  2,611
  2,971
  3,376
  3,829
  4,330
  4,879
  5,474
  6,116
  6,802
  7,514
  8,288
  9,103
  9,960
  10,858
  11,797
  12,776
  13,795
  14,856
  15,960
  17,106
  18,296
  19,532
  20,816
  22,151
  23,538
  24,979
  26,476
  28,035
  29,658
Operating income, $m
  619
  1,055
  1,563
  2,144
  2,800
  3,531
  4,337
  5,216
  6,167
  7,189
  8,299
  9,457
  10,681
  11,970
  13,322
  14,738
  16,217
  17,758
  19,364
  21,036
  22,774
  24,581
  26,459
  28,412
  30,443
  32,555
  34,752
  37,039
  39,420
  41,901
EBITDA, $m
  715
  1,172
  1,703
  2,311
  2,996
  3,760
  4,602
  5,521
  6,515
  7,583
  8,723
  9,934
  11,213
  12,559
  13,972
  15,451
  16,995
  18,606
  20,283
  22,029
  23,845
  25,732
  27,695
  29,734
  31,855
  34,061
  36,356
  38,745
  41,232
  43,823
Interest expense (income), $m
  12
  21
  33
  48
  65
  84
  105
  129
  155
  184
  215
  248
  283
  320
  360
  401
  445
  491
  538
  588
  639
  693
  749
  807
  867
  930
  995
  1,063
  1,133
  1,206
  1,283
Earnings before tax, $m
  598
  1,022
  1,515
  2,079
  2,716
  3,426
  4,208
  5,061
  5,983
  6,975
  8,051
  9,174
  10,361
  11,610
  12,921
  14,293
  15,726
  17,220
  18,777
  20,396
  22,081
  23,832
  25,653
  27,545
  29,513
  31,560
  33,689
  35,906
  38,214
  40,618
Tax expense, $m
  161
  276
  409
  561
  733
  925
  1,136
  1,366
  1,616
  1,883
  2,174
  2,477
  2,797
  3,135
  3,489
  3,859
  4,246
  4,649
  5,070
  5,507
  5,962
  6,435
  6,926
  7,437
  7,969
  8,521
  9,096
  9,695
  10,318
  10,967
Net income, $m
  436
  746
  1,106
  1,518
  1,983
  2,501
  3,071
  3,694
  4,368
  5,092
  5,877
  6,697
  7,563
  8,475
  9,432
  10,434
  11,480
  12,571
  13,707
  14,889
  16,119
  17,397
  18,726
  20,108
  21,545
  23,039
  24,593
  26,211
  27,896
  29,651

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  1,947
  2,448
  3,026
  3,685
  4,425
  5,248
  6,152
  7,136
  8,199
  9,340
  10,556
  11,845
  13,207
  14,640
  16,142
  17,713
  19,354
  21,064
  22,844
  24,696
  26,622
  28,623
  30,702
  32,863
  35,109
  37,445
  39,873
  42,400
  45,031
  47,770
Adjusted assets (=assets-cash), $m
  1,947
  2,448
  3,026
  3,685
  4,425
  5,248
  6,152
  7,136
  8,199
  9,340
  10,556
  11,845
  13,207
  14,640
  16,142
  17,713
  19,354
  21,064
  22,844
  24,696
  26,622
  28,623
  30,702
  32,863
  35,109
  37,445
  39,873
  42,400
  45,031
  47,770
Revenue / Adjusted assets
  1.498
  1.498
  1.498
  1.498
  1.498
  1.498
  1.498
  1.498
  1.498
  1.498
  1.498
  1.498
  1.498
  1.498
  1.498
  1.498
  1.498
  1.498
  1.498
  1.498
  1.498
  1.498
  1.498
  1.498
  1.498
  1.498
  1.498
  1.498
  1.498
  1.498
Average production assets, $m
  697
  876
  1,084
  1,319
  1,584
  1,879
  2,202
  2,555
  2,935
  3,344
  3,779
  4,241
  4,728
  5,241
  5,779
  6,342
  6,929
  7,541
  8,179
  8,842
  9,531
  10,248
  10,992
  11,766
  12,570
  13,406
  14,276
  15,180
  16,122
  17,103
Working capital, $m
  -38
  -48
  -59
  -72
  -86
  -102
  -120
  -139
  -160
  -182
  -206
  -231
  -257
  -285
  -314
  -345
  -377
  -410
  -445
  -481
  -518
  -557
  -598
  -640
  -684
  -729
  -776
  -826
  -877
  -930
Total debt, $m
  618
  887
  1,197
  1,551
  1,949
  2,390
  2,875
  3,404
  3,975
  4,588
  5,241
  5,933
  6,664
  7,434
  8,240
  9,084
  9,965
  10,883
  11,840
  12,834
  13,868
  14,943
  16,059
  17,220
  18,426
  19,680
  20,984
  22,341
  23,754
  25,225
Total liabilities, $m
  1,046
  1,315
  1,625
  1,979
  2,376
  2,818
  3,303
  3,832
  4,403
  5,015
  5,668
  6,361
  7,092
  7,861
  8,668
  9,512
  10,393
  11,311
  12,267
  13,262
  14,296
  15,371
  16,487
  17,648
  18,854
  20,108
  21,412
  22,769
  24,181
  25,653
Total equity, $m
  902
  1,133
  1,401
  1,706
  2,049
  2,430
  2,848
  3,304
  3,796
  4,324
  4,887
  5,484
  6,115
  6,778
  7,474
  8,201
  8,961
  9,753
  10,577
  11,434
  12,326
  13,252
  14,215
  15,216
  16,256
  17,337
  18,461
  19,631
  20,849
  22,118
Total liabilities and equity, $m
  1,948
  2,448
  3,026
  3,685
  4,425
  5,248
  6,151
  7,136
  8,199
  9,339
  10,555
  11,845
  13,207
  14,639
  16,142
  17,713
  19,354
  21,064
  22,844
  24,696
  26,622
  28,623
  30,702
  32,864
  35,110
  37,445
  39,873
  42,400
  45,030
  47,771
Debt-to-equity ratio
  0.690
  0.780
  0.850
  0.910
  0.950
  0.980
  1.010
  1.030
  1.050
  1.060
  1.070
  1.080
  1.090
  1.100
  1.100
  1.110
  1.110
  1.120
  1.120
  1.120
  1.130
  1.130
  1.130
  1.130
  1.130
  1.140
  1.140
  1.140
  1.140
  1.140
Adjusted equity ratio
  0.463
  0.463
  0.463
  0.463
  0.463
  0.463
  0.463
  0.463
  0.463
  0.463
  0.463
  0.463
  0.463
  0.463
  0.463
  0.463
  0.463
  0.463
  0.463
  0.463
  0.463
  0.463
  0.463
  0.463
  0.463
  0.463
  0.463
  0.463
  0.463
  0.463

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  436
  746
  1,106
  1,518
  1,983
  2,501
  3,071
  3,694
  4,368
  5,092
  5,877
  6,697
  7,563
  8,475
  9,432
  10,434
  11,480
  12,571
  13,707
  14,889
  16,119
  17,397
  18,726
  20,108
  21,545
  23,039
  24,593
  26,211
  27,896
  29,651
Depreciation, amort., depletion, $m
  97
  117
  140
  167
  196
  229
  266
  305
  348
  394
  425
  477
  531
  589
  649
  713
  779
  847
  919
  993
  1,071
  1,151
  1,235
  1,322
  1,412
  1,506
  1,604
  1,706
  1,811
  1,922
Funds from operations, $m
  533
  863
  1,246
  1,684
  2,179
  2,730
  3,337
  4,000
  4,716
  5,486
  6,302
  7,174
  8,095
  9,064
  10,082
  11,146
  12,259
  13,418
  14,626
  15,883
  17,190
  18,549
  19,961
  21,430
  22,957
  24,545
  26,197
  27,917
  29,708
  31,573
Change in working capital, $m
  -8
  -10
  -11
  -13
  -14
  -16
  -18
  -19
  -21
  -22
  -24
  -25
  -27
  -28
  -29
  -31
  -32
  -33
  -35
  -36
  -37
  -39
  -40
  -42
  -44
  -45
  -47
  -49
  -51
  -53
Cash from operations, $m
  541
  872
  1,257
  1,697
  2,194
  2,746
  3,355
  4,019
  4,737
  5,508
  6,326
  7,199
  8,121
  9,092
  10,111
  11,177
  12,290
  13,451
  14,661
  15,919
  17,227
  18,588
  20,002
  21,472
  23,001
  24,590
  26,244
  27,966
  29,759
  31,626
Maintenance CAPEX, $m
  -61
  -78
  -98
  -122
  -148
  -178
  -211
  -247
  -287
  -330
  -376
  -425
  -477
  -531
  -589
  -649
  -713
  -779
  -847
  -919
  -993
  -1,071
  -1,151
  -1,235
  -1,322
  -1,412
  -1,506
  -1,604
  -1,706
  -1,811
New CAPEX, $m
  -152
  -179
  -207
  -236
  -265
  -294
  -324
  -352
  -381
  -408
  -435
  -462
  -488
  -513
  -538
  -563
  -587
  -612
  -637
  -663
  -689
  -716
  -744
  -774
  -804
  -836
  -870
  -905
  -942
  -981
Cash from investing activities, $m
  -213
  -257
  -305
  -358
  -413
  -472
  -535
  -599
  -668
  -738
  -811
  -887
  -965
  -1,044
  -1,127
  -1,212
  -1,300
  -1,391
  -1,484
  -1,582
  -1,682
  -1,787
  -1,895
  -2,009
  -2,126
  -2,248
  -2,376
  -2,509
  -2,648
  -2,792
Free cash flow, $m
  328
  615
  952
  1,340
  1,780
  2,274
  2,820
  3,419
  4,069
  4,770
  5,514
  6,312
  7,157
  8,048
  8,984
  9,965
  10,991
  12,061
  13,176
  14,337
  15,545
  16,800
  18,106
  19,463
  20,875
  22,342
  23,869
  25,457
  27,111
  28,834
Issuance/(repayment) of debt, $m
  229
  269
  311
  354
  398
  442
  485
  529
  571
  612
  653
  693
  731
  769
  807
  844
  881
  918
  956
  995
  1,034
  1,075
  1,117
  1,160
  1,206
  1,254
  1,304
  1,357
  1,413
  1,471
Issuance/(repurchase) of shares, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  229
  269
  311
  354
  398
  442
  485
  529
  571
  612
  653
  693
  731
  769
  807
  844
  881
  918
  956
  995
  1,034
  1,075
  1,117
  1,160
  1,206
  1,254
  1,304
  1,357
  1,413
  1,471
Total cash flow (excl. dividends), $m
  557
  884
  1,262
  1,693
  2,178
  2,715
  3,305
  3,947
  4,640
  5,382
  6,167
  7,005
  7,888
  8,817
  9,791
  10,809
  11,872
  12,979
  14,132
  15,331
  16,578
  17,875
  19,223
  20,624
  22,081
  23,596
  25,173
  26,814
  28,524
  30,305
Retained Cash Flow (-), $m
  -197
  -232
  -268
  -305
  -343
  -381
  -418
  -456
  -492
  -528
  -563
  -597
  -630
  -663
  -696
  -728
  -760
  -792
  -824
  -857
  -891
  -926
  -963
  -1,001
  -1,040
  -1,081
  -1,124
  -1,170
  -1,218
  -1,268
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  360
  652
  994
  1,388
  1,835
  2,335
  2,887
  3,492
  4,148
  4,854
  5,604
  6,408
  7,258
  8,154
  9,095
  10,081
  11,112
  12,187
  13,308
  14,474
  15,687
  16,948
  18,260
  19,623
  21,041
  22,515
  24,048
  25,644
  27,306
  29,037
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  345
  597
  865
  1,143
  1,422
  1,694
  1,950
  2,182
  2,383
  2,545
  2,661
  2,734
  2,760
  2,737
  2,670
  2,562
  2,418
  2,244
  2,049
  1,839
  1,623
  1,406
  1,197
  999
  819
  657
  516
  397
  298
  219
Current shareholders' claim on cash, %
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Nu Skin Enterprises, Inc. is a direct selling company that develops and distributes personal care products and nutritional supplements, and a range of other products and services. The Company offers anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands. The Nu Skin brand offers a range of products, including ageLOC Me customized skin care system, ageLOC Spa systems and ageLOC Transformation anti-aging skin care system. The Pharmanex product line includes ageLOC Youth nutritional supplement, ageLOC TR90 weight management and body shaping system, and LifePak nutritional supplements. The Company has operations in various geographic regions, including Greater China, North Asia, Americas, South Asia/Pacific, and Europe, the Middle East and Africa (EMEA). It is focused on offering ageLOC Youth nutritional supplement and ageLOC Me personalized skin care system. The Company also offers household products and technology services.

FINANCIAL RATIOS  of  Nu Skin Enterprises Cl A (NUS)

Valuation Ratios
P/E Ratio 25
Price to Sales 1.6
Price to Book 5.4
Price to Tangible Book
Price to Cash Flow 13
Price to Free Cash Flow 15.9
Growth Rates
Sales Growth Rate -1.7%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -12.3%
Cap. Spend. - 3 Yr. Gr. Rate -23%
Financial Strength
Quick Ratio 4
Current Ratio 0
LT Debt to Equity 50.3%
Total Debt to Equity 62.8%
Interest Coverage 19
Management Effectiveness
Return On Assets 10.1%
Ret/ On Assets - 3 Yr. Avg. 10%
Return On Total Capital 13.3%
Ret/ On T. Cap. - 3 Yr. Avg. 14%
Return On Equity 19.2%
Return On Equity - 3 Yr. Avg. 18.4%
Asset Turnover 1.5
Profitability Ratios
Gross Margin 77.3%
Gross Margin - 3 Yr. Avg. 79%
EBITDA Margin 13.5%
EBITDA Margin - 3 Yr. Avg. 13.4%
Operating Margin 10.5%
Oper. Margin - 3 Yr. Avg. 11.7%
Pre-Tax Margin 9.6%
Pre-Tax Margin - 3 Yr. Avg. 10.2%
Net Profit Margin 6.5%
Net Profit Margin - 3 Yr. Avg. 6.6%
Effective Tax Rate 32.9%
Eff/ Tax Rate - 3 Yr. Avg. 35.6%
Payout Ratio 54.5%

NUS stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the NUS stock intrinsic value calculation we used $2279.099 million for the last fiscal year's total revenue generated by Nu Skin Enterprises Cl A. The default revenue input number comes from 0001 income statement of Nu Skin Enterprises Cl A. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our NUS stock valuation model: a) initial revenue growth rate of 28% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for NUS is calculated based on our internal credit rating of Nu Skin Enterprises Cl A, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Nu Skin Enterprises Cl A.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of NUS stock the variable cost ratio is equal to 39.2%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $1135 million in the base year in the intrinsic value calculation for NUS stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Nu Skin Enterprises Cl A.

Corporate tax rate of 27% is the nominal tax rate for Nu Skin Enterprises Cl A. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the NUS stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for NUS are equal to 23.9%.

Life of production assets of 8.9 years is the average useful life of capital assets used in Nu Skin Enterprises Cl A operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for NUS is equal to -1.3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $704.596 million for Nu Skin Enterprises Cl A - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 55.53 million for Nu Skin Enterprises Cl A is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Nu Skin Enterprises Cl A at the current share price and the inputted number of shares is $3.8 billion.

RELATED COMPANIES Price Int.Val. Rating
HLF Herbalife Nutr 54.79 27.58  str.sell
AVP Avon Products 2.16 0.44  str.sell
NHTC Natural Health 22.16 49.70  str.buy
USNA USANA Health S 120.77 129.80  hold
NATR Nature's S 9.19 1.56  str.sell
RELV Reliv Internat 4.76 1.65  str.sell
PG Procter&Gamble 93.83 86.63  hold
ILMN Illumina 319.51 182.51  sell
LFVN Lifevantage 11.58 16.88  buy

COMPANY NEWS

▶ Nu Skin: 3Q Earnings Snapshot   [06:58PM  Associated Press]
▶ Nu Skin Enterprises To Report Third-Quarter 2018 Results   [Oct-02-18 04:13PM  PR Newswire]
▶ Stock Indexes Mixed In Muted Reaction To Jobs Report   [03:04PM  Investor's Business Daily]
▶ Nu Skin: 2Q Earnings Snapshot   [05:13AM  Associated Press]
▶ Tariff losers: Whiskey, Motorcycles and Makeup   [01:02PM  Yahoo Finance Video]
▶ Nu Skin: 1Q Earnings Snapshot   [Apr-26-18 07:50PM  Associated Press]
▶ Top 4 Cosmetics Stocks of 2018   [Apr-08-18 02:40PM  Investopedia]
▶ Nu Skin Enterprises To Report First-Quarter 2018 Results   [Mar-26-18 04:15PM  PR Newswire]
▶ Best Staples Dividend Stock Picks   [Mar-16-18 04:02PM  Simply Wall St.]
▶ Nu Skin beats 4Q profit forecasts   [Feb-15-18 05:57PM  Associated Press]
▶ Nu Skin Q4 Earnings Preview   [09:37AM  Benzinga]
▶ 5 Best Value Picks Based on PEG Ratio   [Jan-24-18 09:23AM  Zacks]
▶ Stocks To Watch: Nu Skin Enterprise Sees Relative Strength Rating Rise To 84   [Dec-26-17 03:00AM  Investor's Business Daily]
▶ Top 4 Cosmetics Stocks of 2017   [Nov-13-17 10:59AM  Investopedia]
▶ Top 10 Direct Sales Companies in USA   [09:45AM  Insider Monkey]
▶ Nu Skin meets 3Q profit forecasts   [Nov-01-17 06:57PM  Associated Press]
▶ Stock Market News For Oct 13, 2017   [Oct-13-17 10:11AM  Zacks]
▶ Nu Skin Enterprises To Host Investor Meeting And Webcast   [Oct-09-17 06:00PM  PR Newswire]
▶ Nu Skin Enterprises To Report Third-Quarter 2017 Results   [Oct-06-17 09:00AM  PR Newswire]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.